GlassScriptPhysician profile
Azeb M Lemma
NPI 1235591975
$5,167.64
in general payments reported to CMS, 2019-2025
50 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $380 · 2023: $1,319 · 2024: $1,530 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,824 · Education: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.53 |
| Education | $760.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $670.90 | 2021-2025 | Darzalex, Imbruvica, Talvey |
| Novartis Pharmaceuticals Corporation | $618.16 | 2022-2025 | Sandostatin, Piqray, Kisqali |
| Astellas Pharma US INC | $382.87 | 2022-2025 | Xtandi, Vyloy, Padcev |
| Pfizer INC. | $320.81 | 2023-2025 | |
| Abbvie INC. | $236.22 | 2023-2025 | |
| Daiichi Sankyo INC. | $231.55 | 2023-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $205.05 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $200.01 | 2021-2025 | Keytruda, Lynparza, Reblozyl |
| Eisai INC. | $197.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $191.26 | 2021-2025 | Enhertu, Calquence |
| E.R. Squibb & Sons, L.L.C. | $178.76 | 2021-2024 | Opdivo, Opdualag |
| Pharmacosmos Therapeutics INC. | $150.24 | 2021-2025 | Monoferric |
| Gilead Sciences, INC. | $139.11 | 2024 | Trodelvy |
| Celgene Corporation | $133.97 | 2023-2025 | Reblozyl, Pomalyst |
| Alexion Pharmaceuticals, INC. | $125.12 | 2023-2024 | Soliris, Ultomiris |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $100.40 | 2022-2025 | Venclexta, Tecentriq, Itovebi |
| Seagen INC. | $89.85 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $75.90 | 2023-2025 | |
| Inari Medical, INC. | $67.08 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genmab U.S., INC. | $54.09 | 2023-2025 | Tivdak |
| Beigene USA, INC. | $48.18 | 2022-2025 | Brukinsa |
| Glaxosmithkline, LLC. | $44.40 | 2022-2025 | Zejula |
| Incyte Corporation | $41.29 | 2023-2025 | Jakafi |
| Amgen INC. | $38.80 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.37 | 2024-2025 | Fruzaqla, Iclusig |
| Adaptive Biotechnologies Corporation | $35.84 | 2024-2025 | Clonoseq |
| Beone Medicines USA, INC. | $35.26 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $34.41 | 2023-2025 | Tazverik, Onivyde |
| Array Biopharma INC | $31.71 | 2025 | Xalkori, Braftovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $31.69 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $30.49 | 2024 | Orgovyx |
| Kyowa Kirin, INC. | $30.17 | 2023-2025 | Poteligeo |
| Morphosys, US INC. | $29.99 | 2021-2022 | |
| Exelixis INC. | $29.46 | 2024 | Cabometyx |
| Emd Serono, INC. | $25.73 | 2025 | |
| Servier Pharmaceuticals LLC | $24.39 | 2025 | |
| Sandoz INC. | $23.45 | 2025 | Jubbonti, Wyost |
| Fresenius Kabi USA, LLC | $22.13 | 2025 | |
| Mirati Therapeutics, INC. | $21.25 | 2023 | Krazati |
| Lilly USA, LLC | $20.30 | 2025 | Jaypirca, Verzenio |
| Coherus Oncology, INC. | $19.80 | 2024 | |
| Taiho Oncology, INC. | $19.66 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $18.88 | 2025 | Libtayo |
| Tersera Therapeutics LLC | $16.50 | 2023 | Zoladex |
| Sun Pharmaceutical Industries INC. | $15.80 | 2023 | Yonsa, Odomzo |
| Pharming Healthcare, INC. | $15.16 | 2023 | Ruconest |
| Pharmaessentia USA Corporation | $15.04 | 2023 | Besremi |
| Acrotech Biopharma INC. | $14.32 | 2025 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $13.66 | 2025 | Qinlock |
| Legend Biotech USA INC. | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azeb Lemma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.